A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
This is an open label single arm, multicenter, phase II study designet To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination
Metastatic Renal Cell Carcinoma
DRUG: Cabometyx
progression free survival (PFS), To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination, 28 month
overall survival (OS), To assess the overall survival (OS), 28 month|objective response rates (ORR), the efficacy based on objective response rates (ORR) according to RECIST 1:1 criteria, 28 month|safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 28 month
This is an open label single arm, multicenter, phase II study designet To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination